MEGAN WALSH: Open Payments
NPI 1588137186 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$821 in 37 payments from 12 companies in 2025. Trend: 2023 $921 · 2024 $1,929 · 2025 $821
Food & beverage: $821
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $203 |
| ABBVIE INC. | 6 | $127 |
| Madrigal Pharmaceuticals | 4 | $108 |
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
| GENZYME CORPORATION | 2 | $76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Janssen Biotech, Inc. | 2 | $51 |
| Ardelyx, Inc. | 2 | $43 |
| Intercept Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
Products named: ENTYVIO, DUPIXENT, REZDIFFRA, RINVOQ, XIFAXAN, TREMFYA, CREON, IBSRELA.
Industry payments across MA — which companies pay providers there.
